Literature DB >> 20662941

Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism.

C T Correia1, A M Coutinho, A F Sequeira, I G Sousa, L Lourenço Venda, J P Almeida, R L Abreu, C Lobo, T S Miguel, J Conroy, L Cochrane, L Gallagher, M Gill, S Ennis, G G Oliveira, A M Vicente.   

Abstract

The brain-derived neurotrophic factor (BDNF), a neurotrophin fundamental for brain development and function, has previously been implicated in autism. In this study, the levels of BDNF in platelet-rich plasma were compared between autistic and control children, and the role of two genetic factors that might regulate this neurotrophin and contribute to autism etiology, BDNF and NTRK2, was examined. We found that BDNF levels in autistic children (n = 146) were significantly higher (t = 6.82; P < 0.0001) than in control children (n = 50) and were positively correlated with platelet serotonin distribution (r = 0.22; P = 0.004). Heritability of BDNF was estimated at 30% and therefore candidate genes BDNF and NTRK2 were tested for association with BDNF level distribution in this sample, and with autism in 469 trio families. Genetic association analysis provided no evidence for BDNF or NTRK2 as major determinants of the abnormally increased BDNF levels in autistic children. A significant association with autism was uncovered for six single nucleotide polymorphisms (SNPs) [0.004 (Z((1df)) = 2.85) < P < 0.039 (Z((1df)) = 2.06)] and multiple haplotypes [5 × 10(-4) (χ((3df)) = 17.77) < P < 0.042 (χ((9df)) = 17.450)] in the NTRK2 gene. These results do not withstand correction for multiple comparisons, however, reflect a trend toward association that supports a role of NTRK2 as a susceptibility factor for the disorder. Genetic variation in the BDNF gene had no impact on autism risk. By substantiating the previously observed increase in BDNF levels in autistic children in a larger patient set, and suggesting a genetic association between NTRK2 and autism, this study integrates evidence from multiple levels supporting the hypothesis that alterations in BDNF/tyrosine kinase B (TrkB) signaling contribute to an increased vulnerability to autism.
© 2010 The Authors. Genes, Brain and Behavior © 2010 Blackwell Publishing Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662941     DOI: 10.1111/j.1601-183X.2010.00627.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  48 in total

Review 1.  Malondialdehyde, Bcl-2, superoxide dismutase and glutathione peroxidase may mediate the association of sonic hedgehog protein and oxidative stress in autism.

Authors:  Ahmad Ghanizadeh
Journal:  Neurochem Res       Date:  2011-12-06       Impact factor: 3.996

2.  Selfness-nonselfness in designing an anti-B19 erythrovirus vaccine.

Authors:  Candida Fasano; Darja Kanduc
Journal:  Self Nonself       Date:  2011-04-01

3.  Prenatal stress differentially alters brain-derived neurotrophic factor expression and signaling across rat strains.

Authors:  E W Neeley; R Berger; J I Koenig; S Leonard
Journal:  Neuroscience       Date:  2011-04-07       Impact factor: 3.590

Review 4.  Using genetic findings in autism for the development of new pharmaceutical compounds.

Authors:  Jacob A S Vorstman; Will Spooren; Antonio M Persico; David A Collier; Stefan Aigner; Ravi Jagasia; Jeffrey C Glennon; Jan K Buitelaar
Journal:  Psychopharmacology (Berl)       Date:  2013-11-30       Impact factor: 4.530

5.  Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.

Authors:  Orna Levran; Einat Peles; Matthew Randesi; Xu Shu; Jurg Ott; Pei-Hong Shen; Miriam Adelson; Mary Jeanne Kreek
Journal:  Pharmacogenomics       Date:  2013-05       Impact factor: 2.533

6.  Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder.

Authors:  Regina Taurines; Monica Segura; Martin Schecklmann; Laura Albantakis; Edna Grünblatt; Susanne Walitza; Thomas Jans; Benjamin Lyttwin; Michael Haberhausen; Frank M Theisen; Berthold Martin; Wolfgang Briegel; Johannes Thome; Christina Schwenck; Marcel Romanos; Manfred Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2014-02-06       Impact factor: 3.575

7.  Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism.

Authors:  Rebecca J Schmidt; Robin L Hansen; Jaana Hartiala; Hooman Allayee; Linda C Schmidt; Daniel J Tancredi; Flora Tassone; Irva Hertz-Picciotto
Journal:  Epidemiology       Date:  2011-07       Impact factor: 4.822

8.  Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study.

Authors:  Logan K Wink; Debra L Reisinger; Paul Horn; Rebecca C Shaffer; Kaela O'Brien; Lauren Schmitt; Kelli R Dominick; Ernest V Pedapati; Craig A Erickson
Journal:  J Autism Dev Disord       Date:  2021-04

9.  Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism.

Authors:  Kristine L P Garcia; Guanhua Yu; Chiara Nicolini; Bernadeta Michalski; Diego J Garzon; Victor S Chiu; Enrico Tongiorgi; Peter Szatmari; Margaret Fahnestock
Journal:  J Neuropathol Exp Neurol       Date:  2012-04       Impact factor: 3.685

10.  Inhibition of striatal-enriched protein tyrosine phosphatase (STEP) activity reverses behavioral deficits in a rodent model of autism.

Authors:  Manavi Chatterjee; Priya Singh; Jian Xu; Paul J Lombroso; Pradeep K Kurup
Journal:  Behav Brain Res       Date:  2020-05-24       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.